Growth rate of different basal cell carcinoma subtypes
Basal cell carcinoma (BCC) subtypes appear to exhibit different biological behaviour [1, 2] . The speed of growth of tumours is one of the factors that can account for their tissue invasiveness. Interviewing patients is currently the only method of measuring the growth of a tumour over time [3, 4] . Few studies have investigated the speed of growth of BCC [5] , moreover this has not been investigated in relation to the different BCC subtypes. Patients affected by BCCs were studied at our clinic between January and December, 2015. BCC subtypes were classified according to the simplified classification under superficial, infiltrative-morpheaform/micronodular, and nodular subtypes. We measured the maximum lateral and depth extension of the surgically removed tumours in millimetres, based on histological samples. We quantified the kinetics of visible growth according to a simplified method [3] ; each patient was asked to recall only the date (T1) when they had first noticed a lesion where the BCC developed later and the time of surgical excision (T2). The rate of growth (ROG) was defined as the ratio between the maximum lateral extension and/or depth in millimetres of the tumour and the time of tumour growth in months (T2-T1). Inclusion criteria included complete surgical excision. Exclusion criteria included: mixed histology of BCCs and an inability to provide precise information about ROG. Statistical analyses were performed using SPSS for Windows (version 15.0; SPSS Inc. Chicago, Il, USA), and BCC subtype groups were compared using the student t-test for differences in ROG; a value of p<0.05 was considered significant. A total of 127 patients with BCCs were invited to participate in the study; of these, 83 refused to participate or their answers were judged to be poorly reliable. The remaining 44 patients (23 male and 21 female) were therefore enrolled in the study. The age of patients in years for the different subtypes was: 66.13 ± 10.88 for superficial subtype; 69.94 ± 9.34 for nodular subtype; and 74.42 ± 8.58 for infiltrative subtype (vs. superficial subtype; p<0.04). [5] and stated that superficial and infiltrative/micronodular subtypes were more at risk of spreading extensively. The ROG is currently the only method for measuring the growth of a tumour over time [6] , and this method has been externally validated, thus confirming its usefulness [7] . Our results indicate a significant difference among the infiltrative/micronodular and nodular subtype versus superficial subtype with regards to depth extension, and a difference in lateral extension of the nodular subtype vs. superficial subtype. This observation is consistent with the typical clinical picture and histological confirmation. In contrast, for lateral extension, the superficial subtype exhibits the highest value and the nodular subtype the lowest value. These observations appear to be the effect of the different ROGs measured. There is indirect evidence supporting the hypothesis that local conditions may favour a certain subtype [8, 9] . These conditions may restrain the depth of superficial subtypes, as well as speed up growth of the nodular or infiltrative subtypes. Sun-damaged skin may represent a tissue permissive stoma environment for nodular and more aggressive subtypes, which have a well-known preference for sun-exposed sites [10] . With ageing and cumulative environmental assault, senescent cells build up in the stoma and secrete factors that can disrupt tissue architecture and/or stimulate cells to proliferate. Local conditions (sun-exposed skin or increasing age) may affect the higher ROG of these more aggressive subtypes vs. the superficial subtype. The main limitation of this study concerns the medical history criteria used for the evaluation of the ROG, which nevertheless remains the only method currently available to assess the growth speed of a tumour. ROG also assumes that tumour growth is constant and linear. Other limitations include the number of patients, the high percentage of lost data, and the lack of precise information provided by a large number of patients. 
Pirfenidone-induced phototoxic reaction in a patient with idiopathic pulmonary fibrosis
Pirfenidone is a novel antifibrotic and anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis (IPF). It has been approved for use in Europe and the USA for IPF under the trade name Esbriet ® (in Korea: Pirespa ® ). Pirfenidone is believed to reduce fibroblast proliferation, regulate transforming growth factor-␤-stimulated collagen production, and reduce the production of fibrogenic mediators [1, 2] . Large-scale clinical trials have revealed that the most common adverse effects of pirfenidone are gastrointestinal symptoms, hepatic dysfunction, skin photosensitivity, and rash [3, 4] . However, only a few published reports describe the cutaneous adverse effects of pirfenidone in detail. Herein, we report a patient with IPF who presented a cutaneous phototoxic reaction to pirfenidone after sun exposure. A 67-year-old man was referred to us with a suspected cutaneous adverse effect of pirfenidone. He had been diagnosed with IPF six months before. Two months later, he started therapy with pirfenidone with a gradually increasing dose, up to 600 mg/d. After participating in outdoor activities in the sunshine for several days, he developed itchy, erythematous skin lesions on the face and dorsum of both hands. The lesions spread rapidly, and the erythema darkened over time. Physical examination revealed diffuse, erythematousto-tan brown patches on the sun-exposed areas of the face and the dorsum of both hands ( figure 1A) . Histopathological examination of a skin biopsy from the forehead revealed exocytosis with liquefaction degeneration of the basal cell layer, blurring the dermal-epidermal junction. Apoptotic keratinocytes and a perivascular and periadnexal lymphohistiocytic infiltration in the papillary and upper reticular dermis were also seen ( figure 1B, C) . These findings were consistent with a cutaneous phototoxic reaction to pirfenidone. After diagnosis, the dosage of pirfenidone was reduced to 400 mg/d and the patient received oral prednisolone (20 mg/d) and topical corticosteroids (desonide; 0.05% cream). In addition, we advised him to avoid sunlight and to use photoprotective clothing and sunscreen when going outside. The cutaneous lesion gradually improved within two weeks, and we tapered off prednisolone. IPF is a fatal chronic lung disease characterized by irreversible loss of lung function. Oral corticosteroids and other immunosuppressants have only limited therapeutic effects. Pirfenidone is a novel oral antifibrotic therapy that has been shown, in three Phase III randomized controlled trials, to be clinically efficient as treatment for IPF, and is considered to be a rather safe drug with good tolerance [3, 4] . Large-scale clinical trials have revealed that the most common adverse effects of pirfenidone are gastrointestinal symptoms, hepatic dysfunction, skin photosensitivity, and rash. The CAPACITY study reported that skin-related photosensitivity reactions were observed in 12.2% of pirfenidone-treated patients, and rash was noted in 32.2%. [3] In the ASCEND study, rash was observed
